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ABSTRACT
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complica-
tions like thromboembolism, continue to be encountered with PED. We studied the 
safety and the efficacy of prasugrel in the management of clopidogrel non-responders 
treated for intracranial aneurysms. 
Methods: 437 consecutive neurosurgery patients were identified between January 2011 
and May 2016. Patients allergic or having <30% platelet-inhibition with a daily 75mg of 
clopidogrel were dispensed 10mg of prasugrel daily (n=20) or 90mg of ticagrelor twice 
daily (n=2). The average follow-up was 15.8 months (SD=12.4 months). Patient clinical 
well being was evaluated with the modified Rankin Scale (mRS) registered before the 
discharge and at each follow-up visit. To control confounding we used multivariable 
mixed-effects logistic regression and propensity score conditioning.
Results: 26 of 437(5.9%) patients (mean of age 56.3 years; 62 women [14,2%]) presented 
with a sub-arachnoid hemorrhage. 1 patient was allergic to clopidogrel and prasugrel 
simultaneously. All the patients receiving prasugrel (n=22) had a mRS<2 on their latest 
follow-up visit (mean=0.67; SD=1.15). In a multivariate analysis, clopidogrel did not 
affect the mRS on last follow-up, p=0.14. Multivariable logistic regression showed that 
clopidogrel was not associated with an increased long-term recurrence rate (odds 
ratio[OR], 0.17; 95%Confidence Interval [CI95%], 0.01-2.70; p=0.21) neither with an 
increased thromboembolic accident rate (OR, 0.46; CI95%, 0.12-1.67; p=0.36) nor 
with an increased hemorrhagic event rate (OR, 0.39; CI95%,0.91-1.64; p=0.20). None 
of the patients receiving prasugrel deceased or had a long-term recurrence nor a 
hemorrhagic event, only 1 patient suffered from mild aphasia subsequent to a throm-
boembolic event. 3 patients on clopidogrel passed during the study: (2) from acute SAH 
and (1) from intra-parenchymal hemorrhage. Clopidogrel was not associated with an 
increased mortality rate (OR, 2.18; CI95%,0.11-43.27; p=0.61). The same associations 
were present in propensity score adjusted models.
Conclusion: In a cohort of patients treated with PED for their intracranial aneu-
rysms, prasugrel (10mg/day) is a safe alternative to clopidogrel resistant, allergic or 
non-responders. 
INTRODUCTION
Since the 2011 FDA approval, PED 
has been a favored option in treating 
cerebral aneurysm(s).15 The PED is a 
self-expanding stent with 30-35% metal 
surface area coverage that diverts blood 
flow from the aneurysm lumen to the 
downstream arteries causing aneurysm 
sac thrombosis.3 However, there is a 
window period until full luminal endo-
thelialization of the PED occurs, during 
which the patient is at a high risk of 
thromboembolic events.11 2,13 The use of 
Dual Anti-Platelet Therapy (DAPT) with 
aspirin and clopidogrel has been recom-
mended for preventing thrombotic 
and hemorrhagic complications that 
occur after the deployment of PEDs.12 
However, Delgado Almandoz JE et al. 
demonstrated that thromboembolic 
complications continue to be encoun-
tered, particularly with PED, despite 
the routine DAPT. Approximately 30% 
of patients exhibit anti-platelet resis-
tance.1 Insufficient platelet inhibition 
in CYP2C19 heterozygotes causes this 
variability in the response to clopidogrel. 
Several centers have replaced clopi-
dogrel with different anti-aggregation 
drugs like prasugrel or ticagrelor in the 
management of these resistant cases.5,14 
Prasugrel and Ticagrelor achieve more 
potent and rapid inhibition of platelet 
aggregation and decreased inter-
subject response variability.6,8 In our 
Study, we identified all the patients 
that were resistant to clopidogrel. They 
were dispensed prasugrel or ticagrelor 
in order to achieve the optimal platelet 
inhibition. This allowed them to under-
take their flow diverting stent treatment. 
We demonstrate the safety and efficacy 
of prasugrel and ticagrelor as alternative 
antiplatelet agents whilst dispensed in 
conjunction with aspirin in clopidogrel 
non-responders. 
1
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were reviewed to determine whether 
any retroperitoneal, gastrointestinal, or 
genitourinary bleeding had occurred.
Exposure variables
The primary exposure variable was the 
treatment (prasugrel or ticagrelor vs 
clopidogrel).
Covariates used for risk adjustment were 
age and gender. The comorbidities used 
for risk adjustment were: hypertension, 
diabetes mellitus, smoking, previous sub 
arachnoid hemorrhage, aneurysm size, 
per-procedural balloon, previous coiling. 
Statistical analysis
To investigate the association of 
clopidogrel exposure and our outcome 
measures we used several methods to 
address confounding. Initially, for binary 
outcomes we used a multivariable 
logistic regression controlling for all the 
covariates mentioned above. In order to 
control for clustering at the physician 
level, we employed mixed effect models 
with physician as a random effects vari-
able. For continuous outcomes, we used 
the corresponding linear regression 
analyses.
In an alternate way to control for 
confounding for binary outcomes we 
employed a propensity score adjusted 
logistic regression model. To derive the 
propensity of receiving clopidogrel we 
developed a prediction model using 
logistic regression, based on all the 
covariates described above. We subse-
quently employed a logistic regression 
with adjustment (stratification) by quan-
tiles (we chose the number of quantiles 
to be 10) of the propensity score. 
Operating physician was again used as 
a random effects variable.
daily or 90mg of Ticagrelor twice daily. 
Prophylactic anti-platelets therapy was 
given as a minimum of 6 months to 1 
year following the procedure.
Outcome variables
The key primary outcome was the 
patients’ Modified Rankin Scale which 
was calculated and registered before 
the discharge of the patients and at 
each follow-up visit. Mortality, throm-
boembolic events and DSA documented 
hemorrhagic accidents, following 
the aneurysm’s pipeline treatment, 
were considered primary outcomes. 
Secondary outcomes were the post 
interventional length of stay and the 
long-term recurrence.
Patient Follow Up
Patients were scheduled for a follow up 
visit with the senior author after 1, 3, 6 
and 18 months following their discharge 
from the institution. 
The efficacy and the safety of the 
prophylactic DAPT post pipeline 
treatment were evaluated on initial post-
operative angiography and follow-up 
angiography when available. Cerebro-
vascular Angiography (digital subtraction 
angiography DSA) was required at their 
6 months visit and then patients were 
followed accordingly to evaluate for 
bleeding recurrence or vessel stenosis. 
Additional information on the number of 
PED used for initial treatment and on the 
stent migration were all collected during 
the follow up (Table 1). Head computed 
tomography scans were compared and 
analyzed by the senior author to docu-
ment any new or recurrent subarachnoid 
or intra-parenchymal hemorrhage, only 
if the patients were to develop new 
insidious symptoms. Medical charts 
METHODS
Cohort creation
We performed a retrospective cohort 
study of all patients undergoing treat-
ment of cerebral aneurysms with flow 
diverting stents in a tertiary referral center 
between January 2011 and May 2016. 
The Institutional Review Board reviewed 
and approved the study protocol. All 
patients received a pipeline embolization 
device (PED; Covidien, Irvine, California). 
The characteristics of the cohort at the 
baseline can be seen in Table 1. 
Treatment protocol
In our institution, patients are pretreated 
with 75mg of clopidogrel daily and at least 
81mg of aspirin daily for 10 days before 
their PED deployment. Some patients 
presenting for their intervention without 
having received the appropriate 10 days 
DAPT were loaded with 325-650mg of 
aspirin and a bolus of anti-aggregate 
drug (600mg of clopidogrel or 40-60mg 
of prasugrel or 90mg of ticagrelor) within 
less than 24 hours to their interven-
tion. We routinely calculated the P2Y12 
platelet inhibition assay (VerifyNow; 
Accumetrics, San Diego, California) for 
all the patients before the procedure. 
Prasugrel was considered when patients 
are allergic, non-responders or resistant 
to clopidogrel. Resistance was defined 
as having (<30%) of platelets P2Y12 
receptor inhibition. 22 patients among 
the 437 did not have a significant platelet 
inhibition (<30%) with clopidogrel, they 
constituted our population. Ticagrelor 
was the final alternative for those whose 
P2Y12 platelet inhibition was still not 
satisfactory with prasugrel. Patients were 
continued after the operation on 75mg 
of clopidogrel daily or 10mg of prasugrel 
Table 1.  Association between outcomes and clopidogrel
Model Long-term 
recurrence
Intra-PED stenosis Thromboembolic 
Complications
Hemorrhagic 
Complications
Mortality
OR(CI95%)  p value OR(CI95%)  p value OR(CI95%)  p value OR(CI95%)  p value OR(CI95%)  p value
Multi-variable 
regression
0.17(0.01 
to 2.70)
0.21 0.44(0.09 to 
2.15)
0.31 0.46(0.12 
to 1.67)
0.24 0.39(0.91 
to 1.64)
0.20 2.18(0.11 
to 43.27)
0.61
Propensity score 
adjustment
0.26(0.22 
to 3.03)
0.28 0.46(0.09 to 
2.44)
0.37 0.39(0.11 
to 1.41)
0.82 0.33(0,08 
to 1.37)
0.13 0.73(0.75 
to 7.17)
0.79
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intra-pipeline stenosis (OR, 0.44; 
CI95%,0.08 to 2.15; p=0.31). This 
was coherent with the propensity 
score adjusted model. (OR, 0.46; 
CI95%, 0.088 to 2.44; p=0.37).
b. Long term recurrence
 None of the 22 patients receiving 
prasugrel or ticagrelor had a long 
term recurrence. Of 374 patients 
receiving clopidogrel, 1,6% suffered 
from a long term recurrence rate 
with a mean of 0.02(SD=0.13). A 
univariate analysis of the effect 
of clopidogrel on the long term 
recurrence rate does not show 
any correlation between the two 
variables (OR, 0.27; CI95%, 0.03 
to 2.41; p=0.24). In a multivariable 
mixed-effects logistic regression, 
clopidogrel was not associated 
with an increased long term recur-
rence (OR, 0.17; CI95%, 0.01 to 
2.70; p=0.21). This was consistent 
with the propensity score adjusted 
model (OR, 0.26; CI95%, 0.02 to 
3.03; p=0.28). (Table.2)
Safety of prasugrel and ticagrelor 
c. Post PED complications
 Of 22 patients receiving prasugrel 
and ticagrelor the mean of post-
procedural complications is 0.19 
(SD=0.40), only 1 patient developed 
an arterio-venous V3 fistula and 1 
other patient had an ophtalmoplegia 
and a ptosis of the left eye. Of 374 
patients receiving Clopidogrel, the 
mean post PED complications was 
0,53(SD=0.23). A univariate analysis 
of the effect of clopidogrel on the 
post pipeline complication rate is 
associated with an increased post 
pipeline complication rate (OR, 
0.24; CI95%, 0.08 to 0.70; p=0.01). 
In a multivariable mixed-effects 
logistic regression, clopidogrel is 
also associated with an increased 
post pipeline complication rate 
(OR, 0.28; CI95%, 0.08 to 1.01; 
p=0.05). This was consistent with 
the propensity score adjusted model 
where p-value was slightly superior 
to 0.05 (OR, 0.27; CI95%, 0.07 to 
1.03; p=0.055). 
received prasugrel and 2 received 
ticagrelor (Mean=0.0074; SD= 0.0858). 
7 patients were lost for follow-up after 
their intervention (6 from the clopidogrel 
group and 1 from the prasugrel group). 
1 patient was reported allergic to clopi-
dogrel and prasugrel. (Table 1)
 Efficacy of prasugrel and ticagrelor 
a. Intra-pipeline stenosis
 Of 369 patients receiving clopido-
grel, 23(6.1%) of the patients had an 
intra-PED stenosis. 
 In the group of patients receiving 
prasugrel & ticagrelor the mean 
of intra-pipeline stenosis was 
0.117(SD=0.33), only 2 patients 
had an intra-pipeline stenosis: 
1(5%) receiving prasugrel the other 
ticagrelor. The mean of intra-pipe-
line stenosis with patients receiving 
clopidogrel was 0.071(6.7%; 
SD=0.26). A univariate analysis of 
the effect of clopidogrel on the 
thromboembolic complication 
rate did not show any correlation 
between the two variables (OR, 
0.58; CI95%, 0.12 to 2.70; p=0.48). 
In a multivariable mixed-effects 
logistic regression, clopidogrel was 
not associated with an increased 
Patients who were lost to follow up were 
not included in the original analysis. In 
sensitivity analysis, all the above analyses 
were repeated used multiple imputa-
tions for the patients lost to follow up. 
We created 5 imputed datasets. The 
directions of the observed associations 
did not change and these results are not 
reported further.
Regression diagnostics were performed 
for all analyses. Given that the long-term 
recurrence was 2% in a study sample of 
437 patients, we had an 80% power to 
detect a difference in long-term recur-
rence as small as 13.4%, at an α-level 
of 0.05. All probability values were the 
result of two sided tests. Stata version 
13 (StataCorp, College Station, TX) was 
used for statistical analysis.
RESULTS
Demographic characteristics
Between 2011 and 2016, a total of 437 
patients (mean of age 56.3 years; 62 
women [14,2%]) underwent treatment 
with PED in our institution. 26 (5.9%) 
patients presented with an acute sub-
arachnoid hemorrhage (SAH). 374 
received clopidogrel [361 with aspirin, 
9 with Coumadin, 4 with rivaroxaban], 
20 (4.6%; Mean= 0.047; SD= 0.2117) 
Table 2.  Patient characteristics
Clopidogrel Prasugrel - Ticagrelor
374 22
No Mean SD Mean SD
Age (years) 56.25 13.29 57.31 13.55
Sex 1.15 0.36 1.23 0.43
Hypertension 0.51 0.50 0.54 0.51
Smoking 0.50 0.50 0.65 0.49
Aneurysm size (mm) 9.11 5.87 12.93 10.93
Previous SAH 0.10 0.30 0.15 0.37
Adjunctive Coiling 0.74 0.26 0.08 0.27
Stent migration 0.01 0.09 0.04 0.19
Number of stents per 
patient
1.21 0.56 1.32 0.57
mRS on last follow up 0.32 0.75 0.67 1.15
3
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not associated with an increased 
mortality rate (OR, 2.18; CI95%, 0.11 
to 43.27; p=0.61). This persisted in 
a propensity score adjusted model 
(OR, 0.73; CI95%,0.75 to 7.17; p=0.79). 
(Table.2)
g. Latest clinical status
 Of 22 patients receiving prasugrel 
or ticagrelor, All the patients had a 
mRS<=2 on their latest follow-up 
visit with a mean of 0.67(SD= 1.15). 
98.4% of 374 patients receiving 
clopidogrel had a mRS =<2 on their 
latest follow-up visit with a mean of 
0.32(SD= 0.75). (Figure.1) in a multi-
variate analysis were the latest mRS 
is a dependent variable, clopidogrel 
did not affect the mRS score on last 
follow-up, p=0.14. (Figure.1)
h. Post interventional hospital stay
 Of 22 patients receiving prasugrel 
or ticagrelor, the mean of their post 
interventional length of stay was 3 
days (SD= 6.20). (Figure.1) Of 374 
patients receiving clopidogrel the 
mean of the post procedural stay 
was 1.81 days (SD= 2.67). In a multi-
variate analysis clopidogrel did not 
affect the patients’ post operational 
length of stay, p=0.94. 
to 1.33; p=0.13). In a multivariable 
mixed effect logistic regression, 
clopidogrel was not associated with 
an increased hemorrhagic event 
rate (OR, 0.39; CI95%, 0.91 to 1.64; 
p=0.20). We found similar results 
with the propensity score adjusted 
model (OR, 0.33; CI95%, 0.08 to 1.37; 
p=0.13).
f. Mortality
 Patients receiving clopidogrel had 
a mean mortality rate 0.02(2.67%; 
SD=0.15). (Figure.1) 9 patients were 
lost: 6 patients dying from various 
non PED related events such as 
severe sepsis (1), malignant hyperten-
sion with large middle cerebral artery 
infarct (1), severe gastro-intestinal 
complication (1), non reported cause 
of death (3). Only 3 patients from this 
group were announced dead from 
acute SAH (2) and intra-parenchymal 
hemorrhage (1). None of the patients 
receiving prasugrel and ticagrelor 
were lost. A univariate analysis of the 
effect of clopidogrel on the mortality 
rate does not show any correlation 
between the two variables, (OR, 
0.61; CI95%, 0.75 to 5.03; p=0.65). 
In a multivariable mixed effect 
logistic regression, clopidogrel was 
d. Thromboembolic complications
 Of 374 patients prescribed clopido-
grel, the mean of thromboembolic 
events was 0.72(SD=0.26). While 28 
(7.4%) patients receiving clopidogrel 
had thromboembolic complications, 
only 1 patient dispensed prasugrel 
suffered from word finding difficulty. 
A univariate analysis of the effect of 
clopidogrel on the thromboembolic 
complication rate does not show any 
correlation between the two vari-
ables (OR, 0.43; CI95%, 0.14 to 1.32; 
p=0.14). We found similar results in 
a multivariable mixed-effects logistic 
regression (OR, 0.46; CI95%, 0.12 to 
1.67; p=0.36) and a propensity score 
adjusted model (OR, 0.39; CI95%, 
0.11 to 1.41; p=0.82).
e. Hemorrhagic complications
 None of the patients receiving 
prasugrel or ticagrelor suffered from 
hemorrhagic complication. Of 374 
patients receiving clopidogrel the 
mean of the hemorrhagic compli-
cations was 0.45(5.6%; SD=0.21). 
A univariate analysis of the effect 
of clopidogrel on the hemorrhagic 
complication rate does not show 
any correlation between the two 
variables (OR, 0.36; CI95%, 0.10 
Figure 1.  Graph showing the mean values of the clinical outcomes according to the prescribed antiplatelet drug
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65% discharged within two days. This 
goes in line with the series of Stetler who 
also was able to discharge his patients 
on prasugrel on day 1 postoperatively.14 
We may reckon that prasugrel would 
not only be efficacious, it could be 
safe whilst dispensed in this context. 
This patient-safety model is definitely 
multifactorial and it might not be plainly 
related to the use of prasugrel. Although, 
we might imply that prasugrel would not 
be adversely interfering with the patient’s 
clinical wellbeing. 
There is still no clear indication for 
the use of prasugrel as an alternative 
treatment for patients’ resistance to 
clopidogrel during the placement of PED. 
The main concern of clinicians is the 
increased bleeding risks associated with 
its use as shown in several cardiovascular 
studies.9,17 However, the difference in 
end organ result response (brain vs. 
cardiac muscle), tortuosity of intracra-
nial vasculature, and amount of metal 
implanted make it ineffective to simply 
apply cardiac literature to intracranial 
procedures.5  Akbari et al  1 presented their 
experience with prasugrel and aspirin 
in a cohort of 25 patients undergoing 
different neuro-endovascular  proce-
dures, nine of which undergoing PED 
placement. They observed a significant 
increase in hemorrhagic complications 
(19.4% vs. 3.6%; p=0.02) in the prasugrel/
aspirin group as compared to patients 
treated with clopidogrel/aspirin. Jones 
et al tried using low dose prasugrel in 
two cases following PED implantation 
in patients who showed hypo-respon-
siveness to clopidogrel. Both patients 
did well with no thromboembolic or 
hemorrhagic complications.6 Our series 
of patients treated with PED placement 
who were started on prasugrel due to 
hypo-responsiveness to clopidogrel is 
the largest so far. We did not observe any 
ischemic events related to thromboem-
bolism or in-stent thrombosis. We also 
did not find an increased risk of bleeding 
in those patients. Whether our patients 
fall into a subgroup of patients, which 
has a lower propensity to have bleeding 
complications with prasugrel, or these 
results are due to serendipity alone is not 
clear. Conclusions cannot be drawn at 
this level, and more investigations should 
be warranted to study the efficacy and 
safety of prasugrel in patients treated 
endovascularly with PED placement who 
patients who were on both aspirin 
and prasugrel could explain these 
results, as the use of DAPT with aspirin 
and prasugrel would be expected to 
increase the relative risk of bleeding 
by 30% compared to aspirin and clopi-
dogrel.8,17 Interestingly, the greatest 
benefit with prasugrel vs. clopidogrel 
in the TRITON-TIMI 38 study was seen 
in high-risk patients especially diabetics 
or those who suffered an ST-segment 
elevation myocardial infarction, where 
the major adverse cardiac events’ reduc-
tion with prasugrel was not paralleled by 
an increased risk of bleeding.9 This may 
infer that there are certain subgroups 
of patients who are at a decreased risk 
of the hemorrhagic adverse events 
from prasugrel use. The incidence of 
thromboembolic complications was 
approximately akin in the aspirin/clopi-
dogrel group (7.4%) and in the aspirin/
prasugrel group (5%). This was not similar 
to the extrapolated results of many 
studies present in the cardiac literature 
that demonstrated superior reduction of 
ischemic events using prasugrel as part 
of DAPT compared to clopidogrel.10,17
Ticagrelor/aspirin combination was used 
only on two patients who either did 
not achieve the desired P2Y12 platelet 
inhibition with prasugrel or were allergic 
to it. One patient had an intra-pipeline 
stenosis and another suffered from a 
post-procedural hemorrhagic compli-
cation manifesting as mild aphasia. 
Conclusions about efficacy and safety 
of ticagrelor in patients with PED cannot 
be drawn from our series because of our 
limited number of patients. In their series 
of 18 patients, Hanel et al presented their 
successful experience with patients 
using ticagrelor for different neuroendo-
vascular procedures as an alternative to 
clopidogrel in nonresponders.5 Further 
investigations in patients undergoing 
treatment with PED and other neuro-
endovascular procedures are needed to 
assess the efficacy and safety profile of 
ticagrelor in hypo-responders and non-
responders to clopidogrel.
It is noteworthy to state that our series 
followed during a mean of 15.8 months 
(SD=12.4 months) have showed no 
regression but an increasingly improve-
ment of the patients’ clinical wellbeing. 
All our patients had a mRS score <=2 
and their mean length of stay in the 
hospital was approximately 3 days with 
DISCUSSION
Using a retrospective cohort of candi-
dates with cerebrovascular aneurysm(s), 
we did not identify any association 
between clopidogrel administration with 
mortality, thromboembolic accidents, 
long term recurrence, intra-pipeline 
stenosis, hemorrhagic events, mRS on 
latest follow-up and post operational 
hospital length of stay. We found that 
clopidogrel is associated with post-
procedural complications. Prasugrel 
and ticagrelor are increasingly adopted 
in clopidogrel resistant individuals 
treated for their cerebral aneurysm(s). 
Compared to clopidogrel, both prasugrel 
and ticagrelor inhibit platelets aggrega-
tion more rapidly and consistently with 
lower rates of inter-subjects variability.16
In the present study, the efficacy of 
prasugrel, depicted by intra-pipeline 
stenosis and long-term recurrence, was 
roughly similar to clopidogrel (6.1% vs. 
5% and 1.6% vs. no recurrence respec-
tively). These results are consistent with 
the more favorable pharmacokinetic and 
pharmacodynamic profiles of prasugrel, 
which affords a more potent and rapid 
inhibition of platelet aggregation.1 They 
are also in line with the Trial to Assess 
Improvement in Therapeutic Outcomes 
by Optimizing Platelet Inhibition with 
Prasugrel–Thrombolysis In Myocardial 
Infarction 38 (TRITON-TIMI 38) where 
clopidogrel-naïve patients with acute 
coronary syndrome scheduled for 
percutaneous coronary intervention 
on prasugrel therapy showed signifi-
cantly reduced rates of ischemic events, 
including patients with cardiac stent 
thrombosis.17 A recent meta-analysis 
done by Patti et al found that switching 
from clopidogrel to prasugrel, in patients 
undergoing percutaneous coronary 
intervention, tended to decrease the 
incidence of major adverse cardiac 
events during follow-up.9 Despite the 
lack of clear evidence supporting its use 
in cerebrovascular procedures, Leslie-
Mazwi et al were the first to report the 
successful use of prasugrel for acute 
in-stent thrombosis in a patient with 
reduced clopidogrel response under-
going elective stent-assisted aneurysm 
coiling.7
In our series, patients on aspirin and 
prasugrel did not have any hemorrhagic 
complications. The small number of 
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4. Gupta R, Moore JM, Griessenauer CJ, Adeeb 
N, Patel AS, Youn R, et al: Assessment of 
Dual Antiplatelet Regimen for Pipeline 
Embolization Device Placement: A Survey of 
Major Academic Neurovascular Centers in the 
United States. World Neurosurg, 2016
5. Hanel RA: Safety and efficacy of ticagrelor 
for neuroendovascular procedures. A 
single center initial experience. Journal of 
Neurointerventional Surgery, 2014
6. Jones GM, Twilla JD, Hoit DA, Arthur AS: 
Prevention of stent thrombosis with reduced 
dose of prasugrel in two patients under-
going treatment of cerebral aneurysms with 
pipeline embolisation devices. Journal of 
NeuroInterventional Surgery 5:e38, 2013
7. Leslie-Mazwi TM, Chandra RV, Oh DC, 
Nogueira RG: Novel use of prasugrel for 
intracranial stent thrombosis. Journal of 
NeuroInterventional Surgery 3:358-360, 2011
8. Mega JL, Close SL, Wiviott SD, Shen L, 
Hockett RD, Brandt JT, et al: Cytochrome 
P450 genetic polymorphisms and the 
response to prasugrel: relationship to phar-
macokinetic, pharmacodynamic, and clinical 
outcomes. Circulation 119:2553-2560, 2009
9. Patti G, Ricottini E, De Luca L, Cavallari 
I: Safety and Efficacy of Switching From 
Clopidogrel to Prasugrel in Patients 
Undergoing Percutaneous Coronary 
Intervention: A Study-level Meta-analysis 
From 15 Studies. J Cardiovasc Pharmacol 
67:336-343, 2016
10. Paul PD, Sara V, Meagan D: Antiplatelet 
Agents in Cardiology: A Report on Aspirin, 
Clopidogrel, Prasugrel, and Ticagrelor. 
Current Pharmaceutical Design 22:1918-
1932, 2016
11. Pistocchi S, Blanc R, Bartolini B, Piotin M: 
Flow diverters at and beyond the level of the 
circle of willis for the treatment of intracranial 
aneurysms. Stroke 43:1032-1038, 2012
12. Qureshi AI, Luft AR, Sharma M, Guterman 
LR, Hopkins LN: Prevention and treat-
ment of thromboembolic and ischemic 
complications associated with endovascular 
procedures: Part I – Pathophysiological and 
pharmacological features. Neurosurgery 
46:1344-1359, 2000
13. Qureshi AI, Luft AR, Sharma M, Guterman 
LR, Hopkins LN: Prevention and treatment of 
thromboembolic and ischemic complications 
associated with endovascular procedures: 
Part II--Clinical aspects and recommenda-
tions. Neurosurgery 46:1360-1375; discussion 
1375-1366, 2000
14. Stetler WR, Chaudhary N, Thompson 
BG, Gemmete JJ, Maher CO, Pandey AS: 
Prasugrel is effective and safe for neuroin-
terventional procedures. J Neurointerv Surg 
5:332-336, 2013
15. Tan LA, Keigher KM, Munich SA, Moftakhar R, 
Lopes DK: Thromboembolic complications 
with Pipeline Embolization Device placement: 
impact of procedure time, number of stents 
and pre-procedure P2Y12 reaction unit (PRU) 
value. J Neurointerv Surg 7:217-221, 2015
are hypo-responders to clopidogrel. 
The higher cost of prasugrel compared 
to clopidogrel should be also taken into 
consideration when prescribing the 
drug.4
LIMITATIONS
While our series is one of the largest to 
date documenting the safety and efficacy 
of prasugrel in the endovascular pipeline 
setting, our study design is limited by the 
small sample size and by the retrospec-
tive nature of data collection. None of 
the patients receiving prasugrel mani-
fested major adverse events. This does 
not definitively show that prasugrel is as 
effective as clopidogrel in the pipeline 
patient population and our results could 
not be extrapolated to all the neuro-
intervention specialized centers. Further 
randomized clinical trials are indispens-
able to display the promising outcome of 
these drugs in what they could replace 
clopidogrel in patients receiving PED 
flow diversion treatment.
CONCLUSION
The key in assuring clopidogrel resistant 
patients long term clinical wellbeing is 
by applying the right anti-aggregation 
protocol. Approximately 30% of the 
patients receiving clopidogrel are 
heterozygote for the CYP2C19 gene 
and showing a hypo-responsiveness 
or resistance (<30% platelet inhibi-
tion). Prasugrel is to be considered in 
clopidogrel resistant and allergic patients 
undergoing flow diversion treatment for 
their intracranial aneurysms. 
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